Global CRO Icon has deepened its longstanding relationship with Cambridge University, agreeing to lead a class on pricing and market access for new drugs.
U.K. outsourcers PolyTherics and Antitope have merged to pool their R&D resources, christening the combined company Abzena and targeting the bustling biomedical hub of Cambridge for new headquarters.
Pfizer, as part of its plodding effort to win over national leaders with its plan to buy AstraZeneca for more than $100 billion, has promised to preserve jobs in the country and talked up the value of British science. But the local academic community has seen giants buy in, take what they need and cut what they don't want.
Anyone looking to start a biotech company should pay close attention to this list. Venture groups, entrepreneurs and increasingly Big Pharma have been concentrating their money and their attention in a few key places, only occasionally straying from the beaten path when funding a high-risk drug development effort.
LONDON--AstraZeneca's top brass can't wait to start rubbing shoulders with scientists at its planned corporate campus in Cambridge, U.K. So the pharma giant has opted to send an advance team of scientists ahead to get the creative juices flowing early on.
AstraZeneca and its stilted R&D division aren't scheduled to move to Cambridge, U.K., until 2016, but the drugmaker can't wait to settle in at what it calls "one of the world's preeminent biosciences hotspots," planning to send an advance team of scientists to plant some collaborative seeds.
AstraZeneca is in the midst of transferring its global R&D base to a $500 million campus in Cambridge, U.K., shouldering up with the famed institution in hopes of replicating other companies' success in biotech hubs and jump-starting its pipeline.
France's Ipsen is the latest drug developer with eyes on Cambridge, MA's booming biotech hub, plotting to move its U.S. R&D activities to Kendall Square.
Walk into Biogen Idec's new complex in Cambridge, MA, and you might notice something's missing--there are no cubicles or private offices in the 6-story, 190,000-square-foot office, reports The Boston Globe.
Over the next three years the pharma company plans to build a $500 million complex on its new campus that will house its U.K. operations for biologics and small molecule research as well as the corporate staff now operating in London.